D'Hooghe Thomas M
Department of Obstetrics and Gynecology, Leuven University Fertility Center, University Hospital Gasthuisberg, Leuven, Belgium.
Curr Opin Obstet Gynecol. 2003 Jun;15(3):243-9. doi: 10.1097/01.gco.0000072859.73466.e3.
This article will present an overview of current and new hormonal and non-hormonal medical treatment in the management of endometriosis, with special emphasis on immunomodulators and aromatase inhibitors.
Recent research shows a very promising role for new hormonal medication (aromatase inhibitors, estrogen and progesterone receptor modulators) and anti-inflammatory drugs (tumor necrosis factor-alpha inhibitors, matrix metalloproteinase inhibitors, cyclooxygenase-2 inhibitors) in the management of endometriosis.
The ideal drug in the treatment of endometriosis alleviates pain and cures sub-fertility without inhibition of ovulation or menstruation and without significant side effects or teratological effects. Such a drug would allow conception during treatment and would fundamentally change the management of endometriosis from a surgical approach to medical management. Although such a drug does not yet exist, promising research using tumor necrosis factor inhibitors indicates that this could become possible in the not too distant future. We strongly recommend testing new medication for the prevention or treatment of endometriosis in the baboon model, an established research model for fundamental and preclinical research in endometriosis.
本文将概述目前用于子宫内膜异位症管理的激素和非激素药物治疗方法，特别强调免疫调节剂和芳香化酶抑制剂。
近期研究表明，新型激素药物（芳香化酶抑制剂、雌激素和孕激素受体调节剂）和抗炎药物（肿瘤坏死因子-α抑制剂、基质金属蛋白酶抑制剂、环氧化酶-2抑制剂）在子宫内膜异位症管理中具有非常广阔的应用前景。
治疗子宫内膜异位症的理想药物应能缓解疼痛、治愈不孕，且不抑制排卵或月经，无明显副作用或致畸作用。这种药物应能在治疗期间实现受孕，并从根本上改变子宫内膜异位症的管理方式，从手术治疗转变为药物治疗。尽管目前尚无此类药物，但使用肿瘤坏死因子抑制剂的有前景的研究表明，在不久的将来这有可能实现。我们强烈建议在狒狒模型中测试预防或治疗子宫内膜异位症的新型药物，狒狒模型是子宫内膜异位症基础和临床前研究的成熟研究模型。
